• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Cramer Says This Major Healthcare Stock Is 'Ridiculously Cheap And Doing So Many Great Things'

    1/8/24 8:53:11 AM ET
    $ABBV
    $BITF
    $COHR
    $GEHC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Finance: Consumer Services
    Finance
    Get the next $ABBV alert in real time by email

    On CNBC’s "Mad Money Lightning Round," Jim Cramer said he likes Realty Income (NYSE:O) and recommends staying with it. "It’s a very steady story," he noted.

    When asked about ImmunoGen, Inc. (NASDAQ:IMGN), he said, "That’s AbbVie’s (NYSE:ABBV) property now, let’s move on."

    Cramer said he is not a buyer of Ramaco Resources, Inc. (NASDAQ:METC). "Let it go up without me," he added.

    Don’t forget to check out our premarket coverage here

    The "Mad Money" host said he doesn’t really know Bitfarms Ltd. (NASDAQ:BITF). "I just feel like it’s just speculative," he added.

    "I think the stock can tread water or go back to the high seventies," Cramer said when asked about Micron Technology, Inc. (NASDAQ:MU).

    Cramer said Coherent Corp. (NYSE:COHR) is a "little too expensive."

    GE HealthCare Technologies Inc. (NASDAQ:GEHC) is "ridiculously cheap," Cramer said, "I think it’s doing so many great things."

    When asked about TKO Group Holdings, Inc. (NYSE:TKO), he said, "I actually don’t understand how to value this company."

    Arm Holdings plc (NASDAQ:ARMH) is "one you want to own," he said. "I think Rene Haas [CEO of ARM] is doing a fantastic job."

    On Nov. 8, the chipmaker reports earnings for the first time since its initial public offering in September.

    Cramer said he is not a Teva Pharmaceutical Industries Limited (NYSE:TEVA) guy.

    Price Action: Shares of Teva gained 4.1% to close at $11.33, while Arm Holdings fell 2% to $67.05 on Friday. TKO fell 0.3% to settle at $78.63, while GE HealthCare gained 0.1% to $76.62 during Friday’s session. Coherent shares gained 1.4% to settle at $41.17, while Micron rose 0.9% to close at $83.45 on Friday. Bitfarms shares fell 7.2%, while Ramaco Resources fell 1.2%. ImmunoGen shares gained 0.4%, while AbbVie gained 0.4% on Friday. Shares of Realty Income rose 0.4% to close at $57.92 during Friday’s session.
    Now Read This: How To Earn $500 A Month From Conagra Brands Stock Following Latest Earnings Report

    Get the next $ABBV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABBV
    $BITF
    $COHR
    $GEHC

    CompanyDatePrice TargetRatingAnalyst
    Micron Technology Inc.
    $MU
    3/19/2026Buy → Hold
    Summit Insights
    Micron Technology Inc.
    $MU
    3/19/2026$450.00 → $500.00Buy
    Needham
    TKO Group Holdings Inc.
    $TKO
    3/5/2026Outperform → Peer Perform
    Wolfe Research
    TKO Group Holdings Inc.
    $TKO
    2/27/2026Buy → Neutral
    Seaport Research Partners
    TKO Group Holdings Inc.
    $TKO
    2/26/2026$235.00 → $250.00Buy
    Pivotal Research Group
    Realty Income Corporation
    $O
    2/25/2026$61.00 → $70.00Outperform
    RBC Capital Mkts
    Realty Income Corporation
    $O
    2/25/2026$67.75 → $70.50Buy
    Stifel
    AbbVie Inc.
    $ABBV
    2/25/2026$260.00Outperform
    RBC Capital Mkts
    More analyst ratings

    $ABBV
    $BITF
    $COHR
    $GEHC
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by GE HealthCare Technologies Inc.

    SCHEDULE 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)

    3/26/26 6:37:20 PM ET
    $GEHC
    Medical Electronics
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Coherent Corp.

    SCHEDULE 13G/A - COHERENT CORP. (0000820318) (Subject)

    3/26/26 5:15:05 PM ET
    $COHR
    Electronic Components
    Technology

    Amendment: SEC Form SCHEDULE 13G/A filed by AbbVie Inc.

    SCHEDULE 13G/A - AbbVie Inc. (0001551152) (Subject)

    3/26/26 3:06:03 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $BITF
    $COHR
    $GEHC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    GE HealthCare announces lead industrial role in largest EU-funded IHI consortium to advance cardio-oncology care across Europe

    COMPASS is one of the largest public‑private partnerships under the European Union's (EU) Innovative Health Initiative (IHI). The consortium aims to advance early detection and prediction of cardiotoxicity in cancer patients and cancer survivors. The initiative will leverage AI, advanced imaging, biomarkers, and integrated care pathways. GE HealthCare (NASDAQ:GEHC) today announced its leading industrial role in the new COMPASS consortium, a five-year initiative focused on improving precision cardio-oncology care and advancing early detection of cardiovascular risks in cancer patients across Europe. COMPASS combines clinical excellence with novel healthcare technology, and with a t

    3/26/26 8:30:00 AM ET
    $GEHC
    Medical Electronics
    Health Care

    Allergan Aesthetics Reinforces Scientific Differentiation and Leadership with 21 Evidence-Based E-Posters at the 2026 Aesthetic & Anti-Aging Medicine World Congress (AMWC)

    - Five scientific e-posters highlight investigational neurotoxin trenibotulinumtoxinE (TrenibotE), demonstrating rapid improvement in glabellar lines (as early as 8 hours), robust and consistent efficacy, and a favorable safety profile across global patient populations- Real-world and clinical data reinforce onabotulinumtoxinA (BOTOX® Cosmetic) as a foundation for high patient satisfaction, natural-looking results, and the gateway to multimodal facial aesthetic treatment plans- Portfolio-wide results demonstrate continued investment in innovative, integrated approaches for patients and practitioners NORTH CHICAGO, Ill., March 26, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company, w

    3/26/26 4:00:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Allergan Aesthetics Ushers in a New Age of Hyaluronic Acid (HA) Injectables with JUVÉDERM® at AMWC Monaco

    Research reveals an industry mindset shift towards 'undetectable†' aesthetics, as people seek a natural-looking, personalized approach and a subtle, rejuvenated appearance that is almost imperceptible1,2,‡Leading healthcare professionals discussed the findings at an Allergan Aesthetics* event at AMWC, which reaffirm 'undetectable' aesthetics, and the positive role of HA injectables in helping to achieve a discreet 'look'1,2,§The latest findings are part of Allergan Aesthetics' ongoing commitment to quality education and helping shape the future of HA injectablesTogether with trusted healthcare practitioners, the JUVÉDERM® Collection of Fillers is committed to advancing a new era of HA inject

    3/26/26 3:00:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $BITF
    $COHR
    $GEHC
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for VYALEV issued to ABBVIE INC

    Submission status for ABBVIE INC's drug VYALEV (ORIG-1) with active ingredient FOSCARBIDOPA AND FOSLEVODOPA has changed to 'Approval' on 10/16/2024. Application Category: NDA, Application Number: 216962, Application Classification: Type 3 - New Dosage Form and Type 4 - New Combination

    10/18/24 4:38:13 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for VYALEV issued to ABBVIE INC

    Submission status for ABBVIE INC's drug VYALEV (ORIG-1) with active ingredient FOSCARBIDOPA AND FOSLEVODOPA has changed to 'Approval' on 10/16/2024. Application Category: NDA, Application Number: 216962, Application Classification: Type 3 - New Dosage Form

    10/17/24 1:29:31 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for SKYRIZI issued to ABBVIE INC

    Submission status for ABBVIE INC's drug SKYRIZI (SUPPL-7) with active ingredient RISANKIZUMAB-RZAA has changed to 'Approval' on 06/18/2024. Application Category: BLA, Application Number: 761262, Application Classification:

    6/21/24 4:38:17 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $BITF
    $COHR
    $GEHC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Micron downgraded by Summit Insights

    Summit Insights downgraded Micron from Buy to Hold

    3/19/26 8:25:02 AM ET
    $MU
    Semiconductors
    Technology

    Needham reiterated coverage on Micron with a new price target

    Needham reiterated coverage of Micron with a rating of Buy and set a new price target of $500.00 from $450.00 previously

    3/19/26 7:49:58 AM ET
    $MU
    Semiconductors
    Technology

    TKO Group Holdings downgraded by Wolfe Research

    Wolfe Research downgraded TKO Group Holdings from Outperform to Peer Perform

    3/5/26 8:17:54 AM ET
    $TKO
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    $ABBV
    $BITF
    $COHR
    $GEHC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Liu Teyin M bought $7,821,723 worth of shares (23,200 units at $337.14), increasing direct ownership by 856% to 25,910 units (SEC Form 4)

    4 - MICRON TECHNOLOGY INC (0000723125) (Issuer)

    1/15/26 7:07:13 PM ET
    $MU
    Semiconductors
    Technology

    Director Bynoe Peter C B bought $150,220 worth of shares (740 units at $203.00), increasing direct ownership by 17% to 5,187 units (SEC Form 4)

    4 - TKO Group Holdings, Inc. (0001973266) (Issuer)

    9/17/25 8:30:03 PM ET
    $TKO
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    EVP, Chief Legal Officer Mcavoy David R. bought $20,988 worth of Ordinary Shares (1,113 units at $18.86), increasing direct ownership by 9% to 13,027 units (SEC Form 4)

    4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)

    9/9/25 4:02:56 PM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $BITF
    $COHR
    $GEHC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Sabag Mark

    4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)

    3/19/26 4:01:11 PM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Xia Howard H.

    4 - COHERENT CORP. (0000820318) (Issuer)

    3/18/26 5:00:55 PM ET
    $COHR
    Electronic Components
    Technology

    Director Lobo Kevin was granted 777 shares (SEC Form 4)

    4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

    3/17/26 4:08:18 PM ET
    $GEHC
    Medical Electronics
    Health Care

    $ABBV
    $BITF
    $COHR
    $GEHC
    Financials

    Live finance-specific insights

    View All

    Teva Releases Q1 2026 Aide Memoire

    TEL AVIV, Israel, March 19, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q1 2026 Aide Memoire is available on the "Investors" page on its website. Q1 2026 Aide Memoire Teva has compiled this document with public information that was previously provided by Teva in order to assist investors ahead of first quarter 2026 results, which are expected to be released on Wednesday, April 29, 2026 at 7am ET, followed by a conference call at 8am ET. The document is based on Teva's prior results, management's previous commentary about Teva's business outlook and data from select independent sources. About Teva Teva Pharmaceutical Indust

    3/19/26 4:30:00 PM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Teva to Host Conference Call to Discuss First Quarter 2026 Financial Results at 8 a.m. ET on April 29, 2026

    TEL AVIV, Israel and PARSIPPANY, N.J., March 19, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its first quarter 2026 financial results on Wednesday, April 29, 2026, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast of the call will be available on Teva's website at: https://ir.tevapharm.com/Events-and-Presentations. Following the conclusion of the call, a replay of the webcast will be

    3/19/26 4:30:00 PM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Realty Income and Apollo to Establish Strategic Partnership

    - Funding Arrangement Will Advance Realty Income's Private Capital Initiative with Leading Asset Manager- Initial Apollo Investment of $1.0 Billion for 49% Equity Interest in Portfolio of Existing U.S. Realty Income Retail Assets- Cost-Efficient Long-Term Equity with 100% Permanent Equity Treatment by Rating AgenciesSAN DIEGO and NEW YORK, March 19, 2026 /PRNewswire/ -- Realty Income Corporation ((Realty Income, NYSE:O), The Monthly Dividend Company®, and Apollo (NYSE:APO) today announced that Apollo-managed funds and affiliates intend to provide a $1.0 billion investment to Realty Income to acquire a 49% interest in a new joint venture entity that is expected to own a diversified portfolio

    3/19/26 4:15:00 PM ET
    $APO
    $O
    Investment Managers
    Finance
    Real Estate Investment Trusts
    Real Estate

    $ABBV
    $BITF
    $COHR
    $GEHC
    Leadership Updates

    Live Leadership Updates

    View All

    GE HealthCare appoints medtech leader Kevin Lobo to Board of Directors

    GE HealthCare (NASDAQ:GEHC) announced today the appointment of Kevin A. Lobo, Chair and Chief Executive Officer of Stryker Corporation (NYSE:SYK), to its Board of Directors effective March 13. Mr. Lobo brings more than 25 years of medical technology, operational, and financial leadership experience. His clinical expertise and track record of driving innovation and scaling global businesses make him well qualified to contribute to GE HealthCare's strategic priorities. "Kevin is a seasoned healthcare executive with a deep understanding of the medical technology landscape. His knowledge and insight will further strengthen our Board as we continue to build a more personalized, connected and s

    3/17/26 9:00:00 AM ET
    $GEHC
    $SYK
    Medical Electronics
    Health Care
    Medical/Dental Instruments

    Coherent to Join the S&P 500

    SAXONBURG, Pa., March 09, 2026 (GLOBE NEWSWIRE) -- Coherent Corp. (NYSE:COHR) ("Coherent," "We," or the "Company"), a global leader in photonics, today announced it will join the S&P 500 index, effective Monday, March 23. Jim Anderson, CEO, said, "Joining the S&P 500 is a testament to the strength of our team, the power of our technology portfolio, and the trust our customers have placed in us. As optical interconnects and photonic solutions become foundational to scaling next-generation AI data center infrastructure, Coherent is uniquely positioned to drive innovation and deliver enhanced value to our shareholders." Regarded as the leading benchmark for U.S. large-cap equities, the S&P

    3/9/26 9:06:18 AM ET
    $COHR
    Electronic Components
    Technology

    Vertiv Holdings, Lumentum Holdings, Coherent, and EchoStar Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600

    NEW YORK, March 6, 2026 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices: NAPCO Security Technologies Inc. (NASD: NSSC) will replace Alexander & Baldwin Inc. (NYSE:ALEX) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, March 13. An investor group comprised of MW Group and funds affiliated with DivcoWest and Blackstone Real Estate is acquiring Alexander & Baldwin in a deal that is expected to close soon, pending final closing conditions.The following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 will take effect before the market opens on M

    3/6/26 6:39:00 PM ET
    $AGX
    $AHRT
    $AIG
    Engineering & Construction
    Consumer Discretionary
    Real Estate
    Finance

    $ABBV
    $BITF
    $COHR
    $GEHC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by TKO Group Holdings Inc.

    SC 13G/A - TKO Group Holdings, Inc. (0001973266) (Subject)

    11/14/24 7:44:25 PM ET
    $TKO
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by GE HealthCare Technologies Inc.

    SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)

    11/12/24 12:53:28 PM ET
    $GEHC
    Medical Electronics
    Health Care

    SEC Form SC 13G filed by Teva Pharmaceutical Industries Limited

    SC 13G - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Subject)

    11/12/24 10:34:14 AM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care